Navigation Links
Medarex Announces 2008 First Quarter Financial Results
Date:5/12/2008

d antibodies targeting PD-1 and CD70 are expected at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in May.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Statement on Cautionary Factors

Except for the historical information presented herein, the statements relating to Medarex's investments and advances related to its products in this press release may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development, uncertainties
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
2. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
3. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
4. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
5. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
6. Medarex to Present at the JPMorgan Small/Mid Cap Conference
7. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
8. Medifast Announces First Quarter 2008 Financial Results
9. Esperanza Announces Support of H.R. 1108, Encourages Congress to Pass FDA Regulation of Tobacco
10. Pregis Announces First Quarter 2008 Financial Results
11. Almost Family, Inc. Announces Exercise of Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
(Date:5/16/2008)...nce of Oral and Overall Health, HARRISBURG, Pa., ...ted,Concordia Dental is celebrating National Smile...a and the British Dental Health Foundation to,prom...h. Beginning May 18,this year,s event is launchin...it the largest independent international dental he...
(Date:5/16/2008)...nefit from calcitriol, an oral form , , ...d vitamin D may cut the risk of death for people w...bout one quarter, a new study suggests. , Duri...hose being treated with calcitriol, an oral form o...eath lowered by 26 percent when compared with thos...
(Date:5/16/2008)...niors and People With,Disabilities, OAKLAND, Cali...,homecare workers across the state are outraged by...rs of service, wages and benefits,which would for...d the,people they serve deeper into poverty. They ...nd people with disabilities from Schwarzenegger,s,...
Breaking Medicine News(10 mins):Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2
...ny issue of making a one-year rural stint compulso...umani Ramadoss Friday.// A proposal on the issue ... cabinet, the minister told reporters after the se...erial steering group of the National Rural Health ...
...alf-marathon here Monday in his bid to complete 24...e 100,000 pounds for cancer// research. "The 'Gre...d. The London-based Young, 32, plans to run 314.4...t 1, and travel for 130 hours by plane as part of ...
...f babies could be saved by the easiest and most na...search project conducted by field workers in remot...ng babies with in an hour of being born could almo...elay of even one day from the mother’s breast coul...
... to high pollution levels can increase people’s su...Japan have found that the risk of stroke from poll...y breathing and heart problems are associated with...r pollution rather than variations in hourly level...
Other Medicine News:Health News:Compulsory Rural Stint for Doctors: Ramadoss 2Health News:Breast Feeding - The Key in Fighting Child Mortality in Africa 2Health News:Stroke Linked to High Pollution Levels 2
(Date:5/15/2008)... - Unprecedented amount of research reflects dept...s worldwide to develop new treatments for ... session to highlight impact of Zometa(R), the lea...ts with early-stage breast cancer, - Four oral se...ntinuous, inhibitor of mTOR, including first resul...
(Date:5/15/2008)...d pressure reductions demonstrated in Blacks, Hisp...es and Obese Individuals, PARSIPPANY, N.J., May 1...today that data presented at the American Society ...Meeting (ASH 2008) in New,Orleans demonstrated tha...ne and olmesartan medoxomil) safely and effectivel...
(Date:5/15/2008)...xcellent results obtained with a newly cleared dev...plaques of interest that are associated with ...BURLINGTON, Mass., May 15 /- InfraReD...t Hospital in Royal Oak, Mich., have,successfully ... patient,undergoing a cardiac catheterization. Thi...
(Date:5/15/2008)...APPENZELL, Switzerland, May 15 /- Erg... Food and Drug Administration (FDA) has,granted or...nt of pulmonary,arterial hypertension (PAH). Tergu...otal Phase II trial in Europe., "The FDA,s grant ...courages and strengthens our development program b...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2James T Glover Appointed to Board of Directors of Varian Inc 5197 1James T Glover Appointed to Board of Directors of Varian Inc 5197 2USC receives nearly 2427 million in funding for new stem cell research facility 18716 1USC receives nearly 2427 million in funding for new stem cell research facility 18716 2IEEE Homeland Security Conference Business Panel to feature experts on technology commercialization 3229 1IEEE Homeland Security Conference Business Panel to feature experts on technology commercialization 3229 2The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 1The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 2The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 3The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 4The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 5The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 6The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 7The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 8The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 9The Ensign Group Inc Reports First Quarter 2008 Earnings 18711 10
...ised of triglycerides and cholesterols, vary with ...activity. All of these factors contribute to serum...rrelate with risk of untoward vascular and cardiac...cal laboratory values are so much in the public ey...rol, making the discussion of plasma lipid test re...
... Corporation notified the CDC that none of its inf...istribution in the United States for the current i...l of nearly half of the anticipated American vacci...c have grown increasingly alarmed about the scarci..., ,It remains to be seen if virulent new strai...
Other Medicine Technology:Analyzers Offer Point-of-Care Lipid Panels 2Analyzers Offer Point-of-Care Lipid Panels 3Rapid Flu Tests May Prove Especially Helpful This Season 2Rapid Flu Tests May Prove Especially Helpful This Season 3
Smaller than the kuglen hook, this manipulator offers excellent grasping or lifting of the nucleus. Blunt finger-like 0.5 mm two-prong tip. Round knurled handle with dull finish. Straight.
Used when dislocating the lens. Great for chopping during phacoemulsification. Helpful in ushering the IOL out of eye. Useful to reduce possibility of iris tuck with anterior chamber IOL placement.
5 mm curved hook with markings at 14 mm and 20 mm from tip. Flat serrated handle with polished finish. Overall length: 4.7 inches.
Flattened hook. Flat serrated handle with polished finish. Hook: #1 size 8 mm. Overall length: 5.3 inches.
Medicine Products: